STAAR Surgical Generates Cash From Operations During Seco...(he Company that the restrictions of the ...),Health

Date:8/3/2009

he Company that the restrictions of the "integrity hold" put in place by the FDA on August 3, 2007 have been removed. The removal of the integrity hold has now allowed the FDA to resume scientific review of the STAAR application for the Toric Implantable Collamer Lens (TICL(TM)) for Myopic/Astigmatic patients.

The Expert Panel Meeting of Japan's Ministry of Health Labor and Welfare regarding the Visian ICL and Visian Toric ICL was held the last week of July. The panel's recommendation is expected within the next two weeks.

Recent Intraocular Lens (IOL) Highlights

• Global IOL sales were $8.5 million versus $8.7 million in the prior year second quarter. Units were up 2.4% during the second quarter and are up one-half of one percent during the first half of the year. Global IOL units increased sequentially 7.5% in the second quarter
• International IOL sales were $6.2 million versus $6.4 million in the prior year second quarter and increased 3% sequentially. During the quarter international IOL unit sales increased by 4% compared with 2008 and 12% sequentially. Units in Japan increased by 5% and units in Germany by 4% during the quarter.
• U.S. IOL sales were flat compared to the second quarter of 2008, at $2.3 million. Silicone IOL sales increased 19% in the second quarter year over year and are up 9% for the first six months of the year due to conversion to NTIOL product lines. Toric IOL sales increased by 2% while Collamer(R) IOL sales were down 13%. U.S. IOL sales increased 8% sequentially.
• Recent regulatory approvals provide additional revenue opportunities for the second half of the year. The nanoFLEX Collamer Aspheric IOL with the nanoPOINT Injector System which allows for implantation through a 2.2 mm incision, and the recently approved Epiphany Injector System for the Afinity(TM) Three-Piece Collamer will be ava
  '/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine news :

1. STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York
2. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
3. Review of STAARs Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume
4. STAAR Surgical Announces Second Quarter 2009 Earnings Release Date And Conference Call
5. Richard A. Meier Appointed to STAAR Surgical Board of Directors
6. STAAR Surgical Completes Common Stock Offering
7. STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
8. STAAR Surgical Announces First Quarter 2009 Earnings Release Date and Conference Call
9. STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
10. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
11. STAAR Surgical Reports 33% Third Quarter Revenue Growth